Literature DB >> 20444881

Nonsteroidal selective androgen receptor modulators enhance female sexual motivation.

Amanda Jones1, Dong Jin Hwang, Charles B Duke, Yali He, Anjaiah Siddam, Duane D Miller, James T Dalton.   

Abstract

Women experience a decline in estrogen and androgen levels after natural or surgically induced menopause, effects that are associated with a loss of sexual desire and bone mineral density. Studies in our laboratories have shown the beneficial effects of selective androgen receptor modulators (SARMs) in the treatment of osteoporosis and muscle wasting in animal models. A series of S-3-(phenoxy)-2-hydroxy-2-methyl-N-(4-cyano-3-trifluoromethyl-phenyl)-propionamide analogs was synthesized to evaluate the effects of B-ring substitutions on in vitro and in vivo pharmacologic activity, especially female sexual motivation. The androgen receptor (AR) relative binding affinities ranged from 0.1 to 26.5% (relative to dihydrotestosterone) and demonstrated a range of agonist activity at 100 nM. In vivo pharmacologic activity was first assessed by using male rats. Structural modifications to the B-ring significantly affected the selectivity of the SARMs, demonstrating that single-atom substitutions can dramatically and unexpectedly influence activity in androgenic (i.e., prostate) and anabolic (i.e., muscle) tissues. (S)-N-(4-cyano-3-trifluoromethyl-phenyl)-3-(3-fluoro,4-chlorophenoxy)-2-hydroxy-2-methyl-propanamide (S-23) displayed full agonist activity in androgenic and anabolic tissues; however, the remaining SARMs were more prostate-sparing, selectively maintaining the size of the levator ani muscle in castrated rats. The partner-preference paradigm was used to evaluate the effects of SARMs on female sexual motivation. With the exception of two four-halo substituted analogs, the SARMs increased sexual motivation in ovariectomized rats, with potency and efficacy comparable with testosterone propionate. These results indicate that the AR is important in regulating female libido given the nonaromatizable nature of SARMs and it could be a superior alternative to steroidal testosterone preparations in the treatment of hypoactive sexual desire disorder.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444881      PMCID: PMC2913771          DOI: 10.1124/jpet.110.168880

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  37 in total

1.  Key structural features of nonsteroidal ligands for binding and activation of the androgen receptor.

Authors:  Donghua Yin; Yali He; Minoli A Perera; Seoung Soo Hong; Craig Marhefka; Nina Stourman; Leonid Kirkovsky; Duane D Miller; James T Dalton
Journal:  Mol Pharmacol       Date:  2003-01       Impact factor: 4.436

2.  Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats.

Authors:  Jeffrey D Kearbey; Wenqing Gao; Ramesh Narayanan; Scott J Fisher; Di Wu; Duane D Miller; James T Dalton
Journal:  Pharm Res       Date:  2006-10-25       Impact factor: 4.200

3.  Selective androgen receptor modulator treatment improves muscle strength and body composition and prevents bone loss in orchidectomized rats.

Authors:  Wenqing Gao; Peter J Reiser; Christopher C Coss; Mitch A Phelps; Jeffrey D Kearbey; Duane D Miller; James T Dalton
Journal:  Endocrinology       Date:  2005-08-11       Impact factor: 4.736

4.  Sexual response after hysterectomy-oophorectomy: recent studies and reconsideration of psychogenesis.

Authors:  L Zussman; S Zussman; R Sunley; E Bjornson
Journal:  Am J Obstet Gynecol       Date:  1981-08-01       Impact factor: 8.661

5.  Enantioselective binding of Casodex to the androgen receptor.

Authors:  A Mukherjee; L Kirkovsky; X T Yao; R C Yates; D D Miller; J T Dalton
Journal:  Xenobiotica       Date:  1996-02       Impact factor: 1.908

6.  Are changes in sexual functioning during midlife due to aging or menopause?

Authors:  L Dennerstein; E Dudley; H Burger
Journal:  Fertil Steril       Date:  2001-09       Impact factor: 7.329

7.  A selective androgen receptor modulator with minimal prostate hypertrophic activity enhances lean body mass in male rats and stimulates sexual behavior in female rats.

Authors:  George F Allan; Pamela Tannenbaum; Tifanie Sbriscia; Olivia Linton; Muh-Tsann Lai; Donna Haynes-Johnson; Sheela Bhattacharjee; Xuqing Zhang; Zhihua Sui; Scott G Lundeen
Journal:  Endocrine       Date:  2007-10-02       Impact factor: 3.633

8.  The role of androgen in the maintenance of sexual functioning in oophorectomized women.

Authors:  B B Sherwin; M M Gelfand
Journal:  Psychosom Med       Date:  1987 Jul-Aug       Impact factor: 4.312

9.  Psychological reactions and sexual life after hysterectomy with and without oophorectomy.

Authors:  J Nathorst-Böös; B von Schoultz
Journal:  Gynecol Obstet Invest       Date:  1992       Impact factor: 2.031

10.  Safety and efficacy of a testosterone metered-dose transdermal spray for treating decreased sexual satisfaction in premenopausal women: a randomized trial.

Authors:  Susan Davis; Mary-Anne Papalia; Robert J Norman; Sheila O'Neill; Margaret Redelman; Margaret Williamson; Bronwyn G A Stuckey; John Wlodarczyk; Karen Gard'ner; Andrew Humberstone
Journal:  Ann Intern Med       Date:  2008-04-15       Impact factor: 25.391

View more
  7 in total

1.  Alanine aminotransferase regulation by androgens in non-hepatic tissues.

Authors:  Christopher C Coss; Matt Bauler; Ramesh Narayanan; Duane D Miller; James T Dalton
Journal:  Pharm Res       Date:  2011-12-14       Impact factor: 4.200

Review 2.  Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications.

Authors:  Zachary J Solomon; Jorge Rivera Mirabal; Daniel J Mazur; Taylor P Kohn; Larry I Lipshultz; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2018-11-30

3.  Effects of a selective androgen receptor modulator (SARM), GSK2849466A, on stress urinary incontinence and bladder activity in rats with ovariectomy-induced oestrogen deficiency.

Authors:  Katsumi Kadekawa; Naoki Kawamorita; Takahiro Shimizu; Masahiro Kurobe; Philip S Turnbull; Sundeep Chandra; Takahito Kambara; Joanna C Barton; Alan J Russell; Naoki Yoshimura
Journal:  BJU Int       Date:  2020-03-20       Impact factor: 5.588

4.  Evaluation of ostarine as a selective androgen receptor modulator in a rat model of postmenopausal osteoporosis.

Authors:  D B Hoffmann; M Komrakova; S Pflug; M von Oertzen; D Saul; L Weiser; T A Walde; M Wassmann; A F Schilling; W Lehmann; S Sehmisch
Journal:  J Bone Miner Metab       Date:  2018-05-21       Impact factor: 2.626

5.  Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral Tissues.

Authors:  Min Pi; Karan Kapoor; Yunpeng Wu; Ruisong Ye; Susan E Senogles; Satoru K Nishimoto; Dong-Jin Hwang; Duane D Miller; Ramesh Narayanan; Jeremy C Smith; Jerome Baudry; L Darryl Quarles
Journal:  Mol Endocrinol       Date:  2015-10-06

6.  Aromatization Is Not Required for the Facilitation of Appetitive Sexual Behaviors in Ovariectomized Rats Treated With Estradiol and Testosterone.

Authors:  Sherri Lee Jones; Stephanie Rosenbaum; James Gardner Gregory; James G Pfaus
Journal:  Front Neurosci       Date:  2019-08-06       Impact factor: 4.677

Review 7.  Selective androgen receptor modulators: the future of androgen therapy?

Authors:  Andrew R Christiansen; Larry I Lipshultz; James M Hotaling; Alexander W Pastuszak
Journal:  Transl Androl Urol       Date:  2020-03
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.